In the RELATIVITY-047 Phase II/III trial combining Bristol Myers Squibb’s Opdivo with the anti-LAG-3 antibody relatlimab, the drug mashup met the study’s primary goal for progression-free survival compared to use of the blockbuster brand alone in metastatic melanoma patients.
The U.S. Food and Drug Administration approved Aveo Oncology’s Fotivda (tivozanib) for adults with relapsed or refractory advanced renal cell carcinoma in people who have had two or more previous systemic therapies.
Regeneron and Sanofi Collaboration Receives Third FDA Drug Approval
Advanced Non-Small Cell Lung Cancer, Approvals, Blockbusters, Chemoradiation, Clinical Trials, FDA, Hedgehog Pathway Inhibitors, Monoclonal Antibodies, New Indications, PD-1/PD-L1 inhibitors, Progression-Free Survival (PFS), R&D, Regeneron Pharmaceuticals, Sanofi, Therapeutics, TumorsRegeneron and Sanofi’s checkpoint inhibitor Libtayo (cemiplimab-rwlc) won U.S. Food and Drug Administration approval for the first-line treatment of patients with advanced non-small cell lung cancer whose tumors have high PD-L1 expression.
Merck’s Keytruda Plus Eisai’s Lenvima Could Open New Standard of Care in Renal Cancer
Blockbusters, Checkpoint Inhibitors, Clinical Data, Clinical Trials, Combination Therapies, Exploratory Analysis, Keytruda, Merck, Overall Response Rate (ORR), Overall Survival (OS), Progression-Free Survival (PFS), R&D, Renal Cell Carcinoma (RCC), TherapeuticsMerck presented new data from the Phase III CLEAR trial (KEYNOTE-581/Study 307) at the virtual 2021 Genitourinary Cancers Symposium of the company’s checkpoint inhibitor Keytruda (pembrolizumab) and Eisai’s tyrosine kinase inhibitor Lenvima (lenvatinib) in renal cell carcinoma.
New Data Reinforce Long-Term Benefit of Venclexta-Based Combination for Relapsed or Refractory CLL
American Society of Hematology (ASH) Annual Meeting, Blockbusters, Chronic Lymphocytic Leukemia (CLL), Clinical Trials, Data, Minimal Residual Disease (MRD), Progression-Free Survival (PFS), R&D, TherapeuticsRoche Group member Genentech announced that new data from the pivotal Phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta (venetoclax)-based combinations in certain people with chronic lymphocytic leukemia (CLL) and provide more evidence on the potential value of minimal residual disease.
Five Prime Therapeutics Inc., in collaboration Zai Lab Limited on the development of bemarituzumab – a novel therapy for front-line advanced non HER2+ gastric or gastroesophageal junction (GEJ) cancer – announced groundbreaking positive topline Phase II results.
Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?
Blockbusters, Clinical Data, Clinical Trials, Combination Therapies, Overall Response Rate (ORR), Overall Survival (OS), Primary Endpoints, Progression-Free Survival (PFS), R&D, Renal Cell Carcinoma (RCC), Secondary Endpoints, Therapeutics, Topline DataMerck and Eisai announced new investigational data demonstrating positive top-line results from the Phase III KEYNOTE-581/CLEAR trial (Study 307).
Denmark-based Genmab A/S announced positive topline data from the second part of the Phase III CASSIOPEIA trial evaluating daratumumab (marketed as Darzalex) monotherapy as maintenance treatment compared to observation for patients with newly diagnosed multiple myeloma that are eligible for autologous stem cell transplant.
Junshi’s Checkpoint Inhibitor Ready to Head to Regulators for Throat Cancer
Biologics License Application (BLA), Checkpoint Inhibitors, China, China National Medical Products Administration (NMPA), Clinical Trials, Conditional Approval, FDA/Regulatory, Interim Analysis, Nasopharyngeal Carcinoma (NPC), Progression-Free Survival (PFS), R&D, Throat CancerJunshi Biosciences, based in Shanghai, China, announced that an Independent Monitoring Committee (IDMC) decided the company’s Phase III JUPITER-02 trial had met the pre-specified primary endpoint at the interim analysis.
Bristol Myers’ Opdivo with Exelixis drug cuts kidney cancer death risk: study
Analysts, Blockbusters, Clinical Data, Clinical Trials, Combination Therapies, European Society for Medical Oncology (ESMO), Immunotherapies, Kidney Cancer, Progression-Free Survival (PFS), R&D, Renal Cell Carcinoma (RCC), Researchers, TherapeuticsBristol Myers’ Opdivo with Exelixis drug cuts kidney cancer death risk: study NEW YORK (Reuters) – Bristol Myers Squibb Co’s cancer immunotherapy Opdivo in combination with Exelixis Inc’s Cabometyx reduced […]